Recovering Recombinant HPIV2 Virus via cDNA Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine development for human parainfluenza viruses (HPIVs) lacks effective tools for generating suitably attenuated, immunogenic, and genetically stable recombinant strains, particularly for HPIV2, which is challenging due to distinct viral serotypes not eliciting significant cross-immunity, and existing vector candidates like measles virus have limitations and adverse effects.
Innovation Solution
The development of methods and compositions for recovering infectious, recombinant human parainfluenza virus type 2 (HPIV2) using cDNA-based systems, introducing defined structural and phenotypic changes, and creating chimeric viruses that incorporate heterologous antigenic determinants from other pathogens to elicit immune responses, including those against multiple HPIV serotypes and other pathogens like measles virus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live attenuated vaccine viruses are derived through serial passage in cell culture, then attenuation and immunogenicity are achieved, but genetic stability and可控性 of attenuation level are compromised
Solution Approach 1:
The patent applies preliminary action by pre-introducing defined attenuating mutations into the viral genome through cDNA construction before virus recovery. This allows the attenuation phenotype to be established in advance with precise genetic control, eliminating the need for serial passage and ensuring both immunogenicity and genetic stability from the outset.
Solution Approach 2:
The patent applies parameter changes by modifying specific genetic parameters (amino acid sequences) in the viral genome to achieve attenuation. By changing specific residues in proteins like L and HN based on homologous sequences from attenuated strains, the virus gains desired attenuation properties while maintaining genetic stability and controllability.
2Manufacturing precision
If recombinant DNA technology is used to recover infectious virus from cDNA, then genetic precision and controllability are improved, but the complexity of the production system increases
Solution Approach 1:
The patent applies segmentation by dividing the viral genome into manageable cDNA segments that can be independently constructed and assembled. The genome is organized into specific segments (L, HN, F, N, P, M, etc.) that can be separately manipulated through recombinant DNA techniques, allowing precise genetic control while simplifying the overall construction process through modular assembly.
3Ease of manufacture
If existing vector candidates like measles virus are used, then vaccine development is facilitated, but adverse effects and safety concerns arise
Solution Approach 1:
The patent applies taking out by extracting the essential vaccine development benefits from existing vector systems while removing the harmful components. Specifically, it adopts the cDNA-based recovery approach and reverse genetics technology from established systems but applies them to HPIV2, eliminating the adverse effects associated with using measles virus or other heterologous vectors.
Data Source
AI summary
Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.